{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:14:18Z","timestamp":1791476058833,"version":"4.3.4"},"reference-count":46,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T00:00:00Z","timestamp":1745625600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.ard.2025.04.022","type":"journal-article","created":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T07:24:05Z","timestamp":1747380245000},"page":"1130-1139","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Disease-modifying antirheumatic drug\u2013free remission in psoriatic arthritis: is it attainable and sustainable? A large longitudinal study"],"prefix":"10.1016","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2319-7777","authenticated-orcid":false,"given":"Selinde V.J.","family":"Snoeck Henkemans","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4402-4165","authenticated-orcid":false,"given":"Marijn","family":"Vis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3787-4552","authenticated-orcid":false,"given":"Gonul Hazal","family":"Koc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1071-7932","authenticated-orcid":false,"given":"Jolanda J.","family":"Luime","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2394-6926","authenticated-orcid":false,"given":"Marc R.","family":"Kok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7870-8330","authenticated-orcid":false,"given":"Ilja","family":"Tchetverikov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Visser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindy-Anne","family":"Korswagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Bijsterbosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0665-5206","authenticated-orcid":false,"given":"Maikel","family":"van Oosterhout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Baudoin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos H.","family":"van der Kaap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8572-1437","authenticated-orcid":false,"given":"Annette H.M. van der","family":"Helm-van Mil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6628-6222","authenticated-orcid":false,"given":"Pascal H.P.","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ard.2025.04.022_bib0001","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1136\/ard-2024-225531","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update","volume":"83","author":"Gossec","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.04.022_bib0002","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2017-211734","article-title":"Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force","volume":"77","author":"Smolen","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.04.022_bib0003","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1093\/rheumatology\/keaa030","article-title":"Remission and low disease activity in psoriatic arthritis publications: a systematic literature review with meta-analysis","volume":"59","author":"Hag\u00e8ge","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2025.04.022_bib0004","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","article-title":"Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021","volume":"18","author":"Coates","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.ard.2025.04.022_bib0005","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001220","article-title":"DMARD-free remission as novel treatment target in rheumatoid arthritis: a systematic literature review of achievability and sustainability","volume":"6","author":"Verstappen","year":"2020","journal-title":"RMD Open"},{"key":"10.1016\/j.ard.2025.04.022_bib0006","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1136\/annrheumdis-2014-207080","article-title":"Disease-modifying antirheumatic drug-free sustained remission in rheumatoid arthritis: an increasingly achievable outcome with subsidence of disease symptoms","volume":"75","author":"Ajeganova","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.04.022_bib0007","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1136\/annrheumdis-2022-222260","article-title":"Treat-to-target dose reduction and withdrawal strategy of TNF inhibitors in psoriatic arthritis and axial spondyloarthritis: a randomised controlled non-inferiority trial","volume":"81","author":"Michielsens","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.04.022_bib0008","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2016-000395","article-title":"Persistence of low disease activity after tumour necrosis factor inhibitor (TNFi) discontinuation in patients with psoriatic arthritis","volume":"3","author":"Huynh","year":"2017","journal-title":"RMD Open"},{"key":"10.1016\/j.ard.2025.04.022_bib0009","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3899\/jrheum.161567","article-title":"Rebound in measures of disease activity and symptoms in corrona registry patients with psoriatic arthritis who discontinue tumor necrosis factor inhibitor therapy after achieving low disease activity","volume":"45","author":"Harrold","year":"2018","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ard.2025.04.022_bib0010","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1002\/art.41716","article-title":"Withdrawing ixekizumab in patients with psoriatic arthritis who achieved minimal disease activity: results from a randomized, double-blind withdrawal study","volume":"73","author":"Coates","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ard.2025.04.022_bib0011","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1177\/039463201302600333","article-title":"Remission of psoriatic arthritis after etanercept discontinuation: analysis of patients\u2019 clinical characteristics leading to disease relapse","volume":"26","author":"Chimenti","year":"2013","journal-title":"Int J Immunopathol Pharmacol"},{"key":"10.1016\/j.ard.2025.04.022_bib0012","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1136\/annrheumdis-2013-204229","article-title":"High incidence of disease recurrence after discontinuation of disease-modifying antirheumatic drug treatment in patients with psoriatic arthritis in remission","volume":"74","author":"Araujo","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.04.022_bib0013","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1007\/s10067-015-2886-1","article-title":"A feasibility study for a randomised controlled trial of treatment withdrawal in psoriatic arthritis (REmoval of treatment for patients in REmission in psoriatic ArThritis (RETREAT (F))","volume":"34","author":"Moverley","year":"2015","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.ard.2025.04.022_bib0014","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1093\/rheumatology\/ken059","article-title":"Frequency and duration of clinical remission in patients with peripheral psoriatic arthritis requiring second-line drugs","volume":"47","author":"Cantini","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2025.04.022_bib0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003296","article-title":"Enhanced treatment strategies and distinct disease outcomes among autoantibody-positive and -negative rheumatoid arthritis patients over 25 years: a longitudinal cohort study in the Netherlands","volume":"17","author":"Matthijssen","year":"2020","journal-title":"PLoS Med"},{"key":"10.1016\/j.ard.2025.04.022_bib0016","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1136\/ard-2024-225534","article-title":"Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis","volume":"83","author":"Kerschbaumer","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.04.022_bib0017","doi-asserted-by":"crossref","first-page":"379","DOI":"10.3899\/jrheum.140693","article-title":"Facilitators and barriers to adherence in the initiation phase of disease-modifying antirheumatic drug (DMARD) use in patients with arthritis who recently started their first DMARD treatment","volume":"42","author":"Pasma","year":"2015","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ard.2025.04.022_bib0018","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1002\/art.21972","article-title":"Classification criteria for psoriatic arthritis: development of new criteria from a large international study","volume":"54","author":"Taylor","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ard.2025.04.022_bib0019","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1080\/03009742.2020.1803398","article-title":"Lessons learned from clinical phenotypes in early psoriatic arthritis: the real-world Dutch south west Early Psoriatic ARthritis study","volume":"50","author":"Kasiem","year":"2021","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.ard.2025.04.022_bib0020","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002706","article-title":"Importance of quick attainment of minimal disease activity for a positive impact on lives of patients with psoriatic arthritis","volume":"8","author":"Snoeck Henkemans","year":"2022","journal-title":"RMD Open"},{"key":"10.1016\/j.ard.2025.04.022_bib0021","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-004062","article-title":"Window of opportunity in psoriatic arthritis: the earlier the better?","volume":"10","author":"Snoeck Henkemans","year":"2024","journal-title":"RMD Open"},{"key":"10.1016\/j.ard.2025.04.022_bib0022","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/j.1365-4632.2008.03753.x","article-title":"A comparison between BSA, PASI, PLASI and SAPASI as measures of disease severity and improvement by therapy in patients with psoriasis","volume":"47","author":"Henseler","year":"2008","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.ard.2025.04.022_bib0023","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/art.23568","article-title":"Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis","volume":"59","author":"Healy","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ard.2025.04.022_bib0024","first-page":"S14","article-title":"The health assessment questionnaire (HAQ)","volume":"23","author":"Bruce","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.ard.2025.04.022_bib0025","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1136\/ard.2006.059451","article-title":"Consensus Dutch health assessment questionnaire","volume":"66","author":"Boers","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.04.022_bib0026","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/art.1780230202","article-title":"Measurement of patient outcome in arthritis","volume":"23","author":"Fries","year":"1980","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ard.2025.04.022_bib0027","doi-asserted-by":"crossref","first-page":"898","DOI":"10.3899\/jrheum.100857","article-title":"Patient global assessment in psoriatic arthritis: a multicenter GRAPPA and OMERACT study","volume":"38","author":"Cauli","year":"2011","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ard.2025.04.022_bib0028","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.3899\/jrheum.110392","article-title":"It\u2019s good to feel better but it\u2019s better to feel good and even better to feel good as soon as possible for as long as possible. response criteria and the importance of change at OMERACT 10: figure 1","volume":"38","author":"Strand","year":"2011","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ard.2025.04.022_bib0029","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1136\/ard.2009.122259","article-title":"Application of the DAREA\/DAPSA score for assessment of disease activity in psoriatic arthritis","volume":"69","author":"Schoels","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.04.022_bib0030","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1136\/ard.2009.117945","article-title":"Evaluation of the appropriateness of composite disease activity measures for assessment of psoriatic arthritis","volume":"69","author":"VP","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.04.022_bib0031","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1136\/annrheumdis-2015-207507","article-title":"Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score","volume":"75","author":"Schoels","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.04.022_bib0032","doi-asserted-by":"crossref","first-page":"e142","DOI":"10.1136\/annrheumdis-2019-215960","article-title":"DAPSA versus cDAPSA: do we need to use CRP?","volume":"79","author":"Gon\u00e7alves","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.04.022_bib0033","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1002\/art.20048","article-title":"Normative values for the Health Assessment Questionnaire disability index: benchmarking disability in the general population","volume":"50","author":"Krishnan","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ard.2025.04.022_bib0034","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1007\/s40265-018-0994-3","article-title":"Tapering and discontinuation of biologics in patients with psoriatic arthritis with low disease activity","volume":"78","author":"Ye","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.ard.2025.04.022_bib0035","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1080\/03009742.2022.2028364","article-title":"Interval prolongation of etanercept in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a randomized controlled trial","volume":"52","author":"Ruwaard","year":"2023","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.ard.2025.04.022_bib0036","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1136\/annrheumdis-2017-211375","article-title":"Clinical and radiological outcomes of 5-year drug-free remission-steered treatment in patients with early arthritis: IMPROVED study","volume":"77","author":"Akdemir","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.04.022_bib0037","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1093\/rheumatology\/keab631","article-title":"de Jong PHP; tREACH group investigators & tREACH group. The likelihood of attaining and maintaining DMARD-free remission for various (rheumatoid) arthritis phenotypes","volume":"61","author":"Luurssen-Masurel","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2025.04.022_bib0038","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1186\/s13075-020-02368-9","article-title":"Early DAS response after DMARD-start increases probability of achieving sustained DMARD-free remission in rheumatoid arthritis","volume":"22","author":"Verstappen","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.ard.2025.04.022_bib0039","doi-asserted-by":"crossref","first-page":"e252","DOI":"10.1016\/S2665-9913(24)00234-0","article-title":"Sustained DMARD-free remission in subgroups of patients with rheumatoid arthritis: an analysis of two prospective cohorts with early arthritis","volume":"7","author":"Heutz","year":"2025","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.ard.2025.04.022_bib0040","unstructured":"Zorginstituut Nederland. Zinnige Zorg\u2014Analyse gebruik biologicals en JAK-remmers bij reumato\u00efde artritis (2017-2021) [Internet]. 2024 [cited 2024 Oct 23]. Available from: https:\/\/www.zorginstituutnederland.nl\/publicaties\/rapport\/2024\/04\/23\/zinnige-zorg\u2014analyse-gebruik-biologicals-en-jak-remmers-bij-reumatoide-artritis"},{"key":"10.1016\/j.ard.2025.04.022_bib0041","doi-asserted-by":"crossref","first-page":"284","DOI":"10.5114\/reum.2017.72625","article-title":"Drug-free remission: the goal of the future in management of patients with rheumatoid arthritis","volume":"55","author":"Filipowicz-Sosnowska","year":"2017","journal-title":"Reumatologia"},{"key":"10.1016\/j.ard.2025.04.022_bib0042","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2022.105418","article-title":"Sustained DMARD-free remission in rheumatoid arthritis\u2014about concepts and moving towards practice","volume":"89","author":"Verstappen","year":"2022","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.ard.2025.04.022_bib0043","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1056\/NEJMra1505557","article-title":"Psoriatic arthritis","volume":"376","author":"Ritchlin","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ard.2025.04.022_bib0044","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2021.12.012","article-title":"Enthesitis in patients with psoriatic arthritis and axial spondyloarthritis\u2014data from the Danish nationwide DANBIO registry","volume":"52","author":"Mathew","year":"2022","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.ard.2025.04.022_bib0045","doi-asserted-by":"crossref","first-page":"241","DOI":"10.32098\/mltj.02.2016.12","article-title":"Assessment of enthesitis in patients with psoriatic arthritis using clinical examination and ultrasound","volume":"6","author":"Kristensen","year":"2016","journal-title":"Muscles Ligaments Tendons J"},{"key":"10.1016\/j.ard.2025.04.022_bib0046","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/ard.2008.102053","article-title":"Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment","volume":"69","author":"Coates","year":"2010","journal-title":"Ann Rheum Dis"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496725009483?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496725009483?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T04:05:02Z","timestamp":1778040302000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496725009483"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":46,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S0003496725009483"],"URL":"https:\/\/doi.org\/10.1016\/j.ard.2025.04.022","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Disease-modifying antirheumatic drug\u2013free remission in psoriatic arthritis: is it attainable and sustainable? A large longitudinal study","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ard.2025.04.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR).","name":"copyright","label":"Copyright"}]}}